Eli Lilly provides update on COVID-19 antibody programmes
Eli Lilly has given an update on its neutralising antibody programmes, including its combination therapy in patients with COVID-19.
List view / Grid view
News
Positive Phase II results for CNS drug neflamapimod
Neflamapimod taken three times a day significantly improved cognition in trial participants with mild-to-moderate dementia with Lewy bodies (DLB).
EMA begins rolling review of BNT162b2 COVID-19 vaccine
The rolling review of BNT162b2 will allow the committee for human medicines (CHMP) to reach a faster decision on a future marketing authorisation application.
Trial supports use of fluvoxamine in patients with mild COVID-19
A clinical trial has demonstrated that the likelihood of hospitalisation was significantly reduced for patients with mild COVID-19 when given fluvoxamine.
FDA issues guidance for COVID-19 vaccine Emergency Use Authorizations
The FDA has released new guidance for sponsors regarding Emergency Use Authorizations for potential COVID-19 vaccines.
Using rafts to enhance bioavailability of ibandronate
Researchers have developed a novel tablet formulation of ibandronate which increases the oral bioavailability of the drug by releasing it from a hydrogel raft formed in the stomach.
Using deep learning to predict drug metabolites and toxicity
Researchers have developed Metabolite Translator, a system that can predict what the in vivo metabolites of a drug could be in order to identify its potential toxicity.
Lopinavir-ritonavir not an effective treatment for COVID-19, study shows
A clinical trial in the UK has shown that lopinavir-ritonavir is not an effective treatment for patients admitted to hospital with COVID-19.
Immunotherapies to treat cervical cancer show promise in Phase II trials
Novel programmed cell death protein 1 immunotherapies for cervical cancer have demonstrated success in two Phase II clinical trials in the US.
Majority of CMO-acquired dose manufacturing facilities in Europe, report says
A new report has found that three quarters of dose manufacturing facilities acquired by dedicated CMOs in 2019 were in Europe.
CEPI establishes centralised COVID-19 vaccine evaluation network
Five labs have been selected by the Coalition for Epidemic Preparedness Innovations (CEPI) to act as a global network for the assessment of COVID-19 vaccine immunogenicity.
Only Italy and India improved pharma economy in 2020, survey finds
Italy and India were found to be the only countries to have improved their pharma economy score in 2020, according to the CPhI Pharma Index.
SMA drug Zolgensma® has “significant therapeutic benefit”, according to interim data
Treatment with Zolgensma® (onasemnogene abeparvovec) resulted in rapid and sustained improvement in motor function in spinal muscular atrophy (SMA) patients.
Navigating the challenges of mass vaccine production
A new opinion piece from Watson-Marlow Fluid Technology Group has been launched.
EMA begins rolling review of AstraZeneca COVID-19 vaccine
The EMA's human medicines committee has initiated a rolling review of AstraZeneca's COVID-19 vaccine candidate to test its efficacy.
